Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus FOAMICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus FOAMICON.
COR-OTICIN vs FOAMICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
FOAMICON is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
1-2 drops in each affected ear twice daily for 7 days.
Adults: 200 mg orally once daily, with or without food.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life 12-15 hours; clinically, steady-state achieved in ~3 days.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Primarily renal (65% unchanged, 15% as inactive metabolites); biliary/fecal 20%.
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid